Study Shows BRCA Mutation Screening Needed Despite Family History


A new study at a single center in Japan found no significant differences in the rate of BRCA mutations between ovarian cancer patients with or without family histories of the mutations and recommends that BRCA1/2 testing be required for all ovarian cancer patients

A new Japanese study has revealed that about 13% of unselected women with ovarian cancer seen at a single center in Japan had BRCA1/2 mutations. The study, published in Cancer, also revealed no significant differences in the rate of BRCA mutations between patients with or without family histories of the mutations.

Researcher Ikuko Sakamoto, MD, of Yamanashi Prefectural Central Hospital, and colleagues pointed out that prior studies of BRCA1/2 mutations conducted in Asian countries, including Japan, have suggested “marked geographical differences in the positive rates of BRCA1/2 mutations,” with mutation rates in the 2% to 6% range compared with rates in the 11% to 17% range in Western countries.

“However, our study, which analyzed whole exons and exon-intron junctions of BRCA1/2 with a next generation sequencer, revealed that the frequency of BRCA1/2 mutations (13%) was comparable to rates reported from Western countries,” wrote Sakamoto and colleagues. “These discrepancies may be due to differences in the experimental protocols.”

The study enrolled 95 unselected women with ovarian cancer seen at Yamanashi Prefectural Central Hospital between 2013 to 2015. Using next generation sequencing, the researchers analyzed these patients for BRCA1/2 mutations.

They found that 12.6% of the patients had BRCA1/2 mutations; five patients (5.3%) had BRCA1 mutations and seven (7.4%) had BRCA2 mutations. Similar rates of mutations were found between women with a familial history (16.7%) and those without a history (10.2%).

“Because the frequency of BRCA1/2 mutations was unexpectedly high in the cases with no family history, we examined the number of family members from whom we were able to obtain family history,” the researchers wrote. “There was no difference in the mean number of family or in the number of female family members.”

The researchers also analyzed the presence of BRCA mutations and their clinical relevance. No difference in age or primary tumor site were found between patients positive for mutations and those negative for mutations. Patients with mutations were diagnosed at more advanced stages with 100% of BRCA-positive cases having stage III or stage IV disease. In addition, 100% of patients positive for mutations had high-grade serous adenocarcinomas.

Based on their results, the researchers recommended that “BRCA1/2 genetic testing be required for all ovarian cancer patients (mainly those with a serous histology and at advanced stages), regardless of family history, race, or age.”

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content